Тимофеев Илья Валерьевич

Онколог
Стаж: более 16 лет

Специализации доктора

Лекарственное лечение опухолей:

  • Рак почки
  • Уротелиальный рак
  • Рак легкого

Образование, тренинги и курсы повышения квалификации

  • Московская медицинская академия им. И.М. Сеченова (в настоящее время — Первый Московский государственный медицинский университет им. И.М. Сеченова). Диплом с отличием.
  • Аспирантура/ординатура на базе отделения биотерапии опухолей Российского онкологического центра им. Н.Н. Блохина (в настоящее время — НМИЦ онкологии им. Н.Н. Блохина)

Дополнительное образование

  • Oregon Health & Science University (Портлант, Орегон, США)
  • Clinique de Genolier (Женева, Швейцария)
  • Workshop on Methods in Clinical Cancer Research – FECS, AACR, ASCO (Флимс, Швейцария)
  • American Cancer Society University (Вашингтон, США)
  • Ersta Hospice (Стокгольм, Швеция)

Научная деятельность

Научные и экспертные советы
Член научного комитета международной Ассоциации по раку почки (Kidney Cancer Association, США)
Член Рабочей группы Международной коалиции по раку почки (International Kidney Cancer Coalition, Нидерланды)
Член Правления Российского общества клинической онкологии (RUSSCO, Россия)
Директор Бюро по изучению рака почки (Россия)
Член IDEA Award Working Group Американского общества клинической онкологии (ASCO, США) с 2017 по 2019 гг.

Членство в профессиональных организациях
Американское общество клинической онкологии (ASCO)
Европейское общество медицинской онкологии (ESMO)
Американская ассоциация по изучению рака (AACR)
Российское общество клинической онкологии (RUSSCO)

Член редакционных коллегий
Российский журнал «Злокачественные опухоли»
Американский журнал «Kidney Cancer»
Главный редактор онкологического портала RosOncoWeb и Газеты RUSSCO

Награды и достижения

Paper 2018-2019

(TOP 10% most downloaded papers)

2020 British Journal of Urology International (издательство Wiley)
First poster in track,

AACR Special Conference on Tumor Immunology and Immunotherapy

2019 Бостон, США
ENDO 2019,

Late-breaking abstract,

Gold ribbon

2019 Новый Орлеан, США
MASCC 2018,

Late-breaking abstract

2018 Вена, Австрия
ASCO MERIT AWARD 2016 Сан-Франциско, США
TOP Poster GU ASCO 2016 2016 Сан-Франциско, США
100 лучших российских инноваций 2013 2014 Роспатент. Москва, РФ
Prix Galien Russia 2013

“Best Research in Russia”

for compound OM-RCA-01

2013 Москва, РФ
EMUC-2013

(EAU-ESMO-ESTRO)

First Prize for Best Oral Presentation

2013 Марсель, Франция
Oncology Forum 2012

Grand prix; Top poster

2012 Будапешт, Венгрия
AACR-AstraZeneca Scholar-in-Training Award 2010 AACR-JCA, Гавайи, США
Зворыкинский проект,

Инновации России

“Золотая сотня”

2009 Москва, РФ
IDEA ASCO Award 2008 ASCO, Чикаго, США
Best Innovation Scientific Project Award 2007 Москва, РФ
ESMO Best Poster Award 2007 ECLU, Швейцария
AACR-Aflac Award 2007 AACR-JCA, Гавайи, США
Certificate of Achievement

for dedication and commitment to the global cancer control mission

2006 Американское онкологическое общество, Вашингтон, округ Колумбия, США
Первый приз 2003 IV конференция молодых онкологов в Украине, Киев, Украина
Золотая медаль Н.И. Пирогова за лучшее исследование молодых ученых в России 2003 Российская академия медицинских наук, Москва, РФ
Сертификат за выдающиеся достижения в онкоиммунологии 2002 Москва, РФ

Публикации

Индекс Хирша 19

Tsimafeyeu I, Volkova M. Management of Patients with Renal Cell Carcinoma during Coronavirus Pandemic: Proposed Algorithm in Russia. Clin Oncol. 2020; 5: 1707.

Mitin T, Dengina N, Chernykh M, Usychkin S, Gladkov O, Degnin C, Chen Y, Nosov D, Tsimafeyeu I, Thomas CR Jr, Tjulandin S. Management of Muscle Invasive Bladder Cancer with Bladder Preservation in Russia: a Survey-Based Analysis of Current Practice and the Impact of an Educational Workshop on Clinical Expertise [published online ahead of print, 2020 Mar 4]. J Cancer Educ. 2020;10.1007/s13187-020-01728-y.

Tsimafeyeu I, Imyanitov E, Zavalishina L, Raskin G, Povilaitite P, Savelov N, Kharitonova E, Rumyantsev A, Pugach I, Andreeva Y, Petrov A, Frank G, Tjulandin S. Agreement between PDL1 immunohistochemistry assays and polymerase chain reaction in non-small cell lung cancer: CLOVER comparison study. Sci Rep. 2020;10(1):3928.

Tsimafeyeu I, Gafanov R, Protsenko S, Semenova A, Oganesyan A, Nurgaliyev N, Krasny S, Bondarenko A, Safina S, Zakurdaeva K. Nivolumab in patients with metastatic renal cell carcinoma and chronic hepatitis C virus infection [published online ahead of print, 2020 Feb 20]. Cancer Immunol Immunother. 2020;69(6):983-988.

Mitin T, Degnin C, Chen Y, Shirvani S, Gillespie E, Hoffe S, Latifi K, Nabavizadeh N, Dengina N, Chernich M, Usychkin S, Kharitonova E, Egorova Y, Pankratov A, Tsimafeyeu I, Thomas CR Jr, Tjulandin S, Likhacheva A. Radiotherapy for Hepatocellular Carcinoma in Russia: a Survey-Based Analysis of Current Practice and the Impact of an Educational Workshop on Clinical Expertise. J Cancer Educ. 2020;35(1):105‐111.

Tsimafeyeu I, Volkova M, Olshanskaia A, Raskin G, Aschuba S, Khochenkova Y, Bondarenko A, Khochenkov D. Expression of Receptor Tyrosine Kinases on Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes in Patients with Renal Cell Carcinoma and Healthy Donors. Oncology. 2020;98(4):252‐258.

Dengina N, Mitin T, Gamayunov S, Safina S, Kreinina Y, Tsimafeyeu I. Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicentre study. ESMO Open 2019;4:e000535. doi:10.1136/ esmoopen-2019-000535

Tsimafeyeu I, Moiseenko F, Orlov S, Filippova E, Belonogov A, Nebesnykh A, Khalimov A, Karabina E, Shikina V, Abdelgafur A, Statsenko G, Titova I, Isaichikov D, Makarnyaeva G, Mordovskiy A, Barkovskaya O, Smirnov A, Gikalo M, Savelov N, Kosov D, Imyanitov E, Demidova I, Tjulandin S. Overall Survival of Patients With ALK-Positive Metastatic Non-Small-Cell Lung Cancer in the Russian Federation: Nationwide Cohort Study. J Glob Oncol. 2019 May;5:1-7.

Tsimafeyeu I, Borisov P, Abdelgafur A, Leonenkov R, Novikova O, Guseva I, Demchenkova M, Mikhailova N, Semenov A, Yurmazov Z, Sivunova I, Ramazanova M, Gamayunov S, Kosov D, Bratslavsky G. Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx. Target Oncol. 2019 Feb;14(1):33-38.

Tsimafeyeu I, Tjulandin S. First-line checkpoint inhibitors in PD-L1-positive patients with advanced urothelial carcinoma. BJU Int. 2019 Apr;123(4):563-565.

Mitin T, Degnin C, Chen Y, Shirvani S, Gillespie E, Hoffe S, Latifi K, Nabavizadeh N, Dengina N, Chernich M, Usychkin S, Kharitonova E, Egorova Y, Pankratov A, Tsimafeyeu I, Thomas CR Jr, Tjulandin S, Likhacheva A. Radiotherapy for Hepatocellular Carcinoma in Russia: a Survey-Based Analysis of Current Practice and the Impact of an Educational Workshop on Clinical Expertise. J Cancer Educ . 2018 Nov 22. doi: 10.1007/s13187-018-1447-0. [Epub ahead of print]

Tsimafeyeu I, Leonenko V, Kuznetsov V, Semenkova E, Bondarenko A, Demidov L. Paraneoplastic vasculitis in patients with metastatic renal cell carcinoma. Cancer Reports. 2018;e1142. https://doi.org/10.1002/cnr2.1142

Zavalishina L, Tsimafeyeu I, Povilaitite P, Raskin G, Andreeva Y, Petrov A, Kharitonova E, Rumyantsev A, Pugach I, Frank G, Tjulandin S. RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer. Virchows Arch . December 2018, Volume 473, Issue 6, pp 719–724.

Tsimafeyeu I. Cytoreductive nephrectomy would not be required in intermediate and poor risk patients with metastatic renal cell carcinoma cancer. Clin Oncol. 2018;3:1502.

McClelland S 3rd, Chernykh M, Dengina N, Gillespie EF, Likhacheva A, Usychkin S, Pankratov A, Kharitonova E, Egorova Y, Tsimafeyeu I, Tjulandin S, Thomas CR Jr, Mitin T. Bridging the Gap in Global Advanced Radiation Oncology Training: Impact of a Web-Based Open-Access Interactive Three-Dimensional Contouring Atlas on Radiation Oncologist Practice in Russia. J Cancer Educ . 2018 Jun 25. doi: 10.1007/s13187-018-1388-7.

Tsimafeyeu I, Zolotareva T, Varlamov S, Zukov R, Petkau V, Mazhbich M, Statsenko G, Safina S, Zaitsev I, Sakaeva D, Popov A, Borisov P, Vladimirova L. Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry. Clin Genitourin Cancer. 2017 Dec;15(6):e1069-e1072.

Dengina N, Tsimafeyeu I, Mitin T. Current Role of Radiotherapy for Renal-Cell Carcinoma: Review. Clin Genitourin Cancer. 2017 Apr;15(2):183-187.

Tyulyandina A, Harrison D, Yin W, Stepanova E, Kochenkov D, Solomko E, Peretolchina N, Daeyaert F, Joos JB, Van Aken K, Byakhov M, Gavrilova E, Tjulandin S, Tsimafeyeu I. Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies. Invest New Drugs. 2017 Apr;35(2):127-133.

Tsimafeyeu I, Khasanova A, Stepanova E, Gordiev M, Khochenkov D, Naumova A, Varlamov I, Snegovoy A, Demidov L. FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma. Clin Transl Oncol. 2017 Feb;19(2):265-268.

Demidova I, Grinevich V, Avdalian A, Imyanitov E, Gikalo M, Savelov N, Novikova I, Samuilenkova O, Tiurin V, Ulianova E, Tsimafeyeu I, Tjulandin S. Detection of ALK rearrangements in 4002 Russian patients: The utility of different diagnostic approaches. Lung Cancer . 2017 Jan;103:17-23.

Tsimafeyeu I. Management of non-clear cell renal cell carcinoma: Current approaches. Urol Oncol . 2017 Jan;35(1):5-13.

Imyanitov EN, Demidova IA, Gordiev MG, Filipenko ML, Kekeyeva TV, Moliaka YK, Gervas PA, Kozhemyako VB, Vodolazhskiy DI, Sergeyeva LA, Fattakhova DU, Iyevleva AG, Mitiushkina NV, Kuligina ES, Barinov AA, Mommaeva MS, Aleksakhina SN, Tsimafeyeu IV, Tjulandin SA. Distribution of EGFR Mutations in 10,607 Russian Patients with Lung Cancer. Mol Diagn Ther . 2016 Aug;20(4):401-406.

Tsimafeyeu I, Ludes-Meyers J, Stepanova E, Daeyaert F, Kochenkov D, Joose JB, Solomko E, Van Akene K, Peretolchina N, Yin W, Ryabaya O, Byakhov M, Tjulandin S. Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models. Eur J Cancer. 2016 Jul;61:20-8.

Tsimafeyeu I, Daeyaert F, Joos JB, Van Aken K, Ludes-Meyers J, Byakhov M, Tjulandin S. Molecular modeling, de novo design and synthesis of a novel, extracellular binding fibroblast growth factor receptor 2 inhibitor alofanib (RPT835). Med Chem . 2016;12(4):303-17.

Tsimafeyeu I. Sunitinib treatment of metastatic renal cell carcinoma in von Hippel-Lindau disease. J Can Res Ther 2015;11:920-2.

Tsimafeyeu I, Bratslavsky G. Fibroblast growth factor receptor 1 as a target for the therapy of renal cell carcinoma. Oncology. 2015;88(6):321-31. doi: 10.1159/000370118.

Tsimafeyeu I, Snegovoy A, Varlamov S, Safina S, Varlamov I, Gurina L, Manzuk L. Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T. Target Oncol. 2015 Sep;10(3):423-7.

Goss PE, Strasser-Weippl K, Lee-Bychkovsky BL, … Tsimafeyeu I, et al. Challenges to effective cancer control in China, India, and Russia. Lancet Oncol 2014; 15: 489–538.

Tsimafeyeu I, Zaveleva E, Stepanova E, Low W. OM-RCA-01, a novel humanized monoclonal antibody targeting fibroblast growth factor receptor 1, in renal cell carcinoma model. Invest New Drugs (2013) 31:1436–1443.

Tsimafeyeu I, Zart JS, Chung B. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma with small primary tumours treated with sunitinib or interferon-α. BJU Int. 2013 Jul;112(1):32-8.

Tsimafeyeu I, Demidov L, Kharkevich G, Petenko N, Galchenko V, Sinelnikov I, Naidzionak U. Phase II, Multicenter, Uncontrolled Trial of Single-Agent Capecitabine in Patients With Non-Clear Cell Metastatic Renal Cell Carcinoma. Am J Clin Oncol. 2012 Jun;35(3):251-4.

Tsimafeyeu, L. Demidov, E. Stepanova, N. Wynn and H. Ta. Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma. Scand J Urol Nephrol. 2011 Apr;45(3):190-5. doi: 10.3109/00365599.2011.552436.

Tsimafeyeu I, Demidov L. Treatment options for renal cell carcinoma in patients with von Hippel-Lindau disease. J Cancer Res Ther. 2010 Oct-Dec;6(4):575-7. doi: 10.4103/0973-1482.77084.

Tsimafeyeu I, Aksel E. Renal Cell Carcinoma in the Russian Federation in 2008. Malign Tumours 2010;1:1-4.

Tsimafeyeu I, Demidov L, Kharkevich G, Petenko N, Volkova M, et al. Granulocyte-Macrophage Colony-Stimulating Factor, Interferon Alpha and Interleukin-2 as Adjuvant Treatment for High-Risk Renal Cell Carcinoma. J Cancer Sci Ther 2010;2:157-159

I. Tsimafeyeu, L. Demidov, A. Madzhuga, O. Somonova, A, Yelizarova. Hypercoagulability as a prognostic factor for survival in patients with metastatic renal cell carcinoma. J Exp Clin Cancer Res. 2009 Mar 2;28:30. doi: 10.1186/1756-9966-28-30.